Tolerance & resistance to ß2-agonist bronchodilators.
Paediatr Respir Rev
; 14(3): 195-8, 2013 Sep.
Article
en En
| MEDLINE
| ID: mdl-23507501
ABSTRACT
For the past half-century, ß2-agonists have been the mainstay of treatment of the bronchoconstriction associated with asthma. Although their usefulness in reversing acute bronchospasm remains undiminished, there is increasing evidence that chronic use may lead to development of tolerance and thus, potentially increasing morbidity and even mortality. In addition, genetic studies have shown that certain individuals carrying specific mutations may be prone to developing resistance to ß2-agonists regardless of the duration of treatment. This article reviews the current evidence regarding the underlying mechanisms that cause or contribute to the development of the resistance, as well as the strategies for the evaluation and management of patients who are at risk for or have developed tolerance to ß2-agonists.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Asma
/
Broncoconstricción
/
Receptores Adrenérgicos beta 2
/
Tolerancia a Medicamentos
/
Agonistas de Receptores Adrenérgicos beta 2
Límite:
Humans
Idioma:
En
Revista:
Paediatr Respir Rev
Asunto de la revista:
PEDIATRIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos